1701. Anal Cancer Awareness and Willingness to Receive Anal Cytology Testing among HIV-Infected Men in Miami.
Session: Poster Abstract Session: HIV: HIV, HPV, and other STDs
Saturday, October 10, 2015
Room: Poster Hall
  • IDWeek2015AposterfinalPDF.pdf (89.9 kB)
  • Background: The incidence of anal cancer among HIV-infected individuals continues to increase despite the success of antiretroviral therapy. Although HIV-infected men who have sex with men (MSM) have the highest rates of anal dysplasia and anal cancer, HIV-infected heterosexual men are also at increased risk. Several HIV caretakers have adopted anal cytology as a screening tool for anal dysplasia and cancer. 

    Methods: One hundred HIV-infected men (73% heterosexual, 27% MSM) attending routine medical visits at an outpatient HIV clinic in Miami, FL completed a questionnaire assessing their awareness of anal cancer and willingness to have anal cytology testing.  Univariate logistic regression analyses were used to examine potential correlates of willingness.

    Results: The study population was 57% non-Hispanic Black, 35% Hispanic, and 8% other race/ethnicity, the mean age was 51 years and approximately 45% of participants had ≥2sexual partners in the last 12 months. The majority of the participants reported knowing little or nothing about anal cancer (22% and 69% respectively), most participants believed they were not at risk of having anal cancer (61%), and only approximately one third of the participants (34%) knew HIV and AIDS increase the chance of anal cancer. Overall most participants (77%) were willing to have anal cytology screening, however the majority of the participants reported not having heard of anal cytology test, were not aware the test was available at the clinic (77% and 60% respectively) and 90% reported never having the test done. In identifying barriers to getting an anal cytology test, the majority of the respondents (60%) identified no specific reason not to have the test; however 21% identified not knowing enough about the test as a barrier. Regression analysis did not identify factors significantly associated with willingness to have anal cytology testing.   

    Conclusion: Although the prospect of anal cytology screening was well accepted among HIV-infected men in the study, the screening tool remains underutilized and individuals had a poor sense of their own personal susceptibility to anal cancer. While randomized data on anal dysplasia and anal cancer screening and treatment are not available, HIV-infected men need to know they are at risk of anal cancer and the possible benefits of anal cytology screening.

    Ryan Karsner, MD1, Tulay Koru-Sengul, PhD2, Gregory Tapia, MPH3, Feng Miao, MS2, Guillermo Prado, PhD4 and Isabella Rosa-Cunha, MD3, (1)Medicine, Jackson Memorial Hospital/University of Miami Miller School of Medicine, Miami, FL, (2)Department of Public Health Sciences, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, (3)Medicine/Div. Infectious Diseases, University of Miami Miller School of Medicine, Miami, FL, (4)Public Health Sciences, University of Miami Miller School of Medicine, Miami, FL


    R. Karsner, None

    T. Koru-Sengul, None

    G. Tapia, None

    F. Miao, None

    G. Prado, None

    I. Rosa-Cunha, None

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 7th with the exception of research findings presented at the IDWeek press conferences.